Approvals for spinal muscular atrophy and chronic kidney disease; Joenja gains expanded approval in APDS; LSD derivative earns Breakthrough status to treat major depressive disorder; and zasocitinib ...
Phase 3 CELESTIMO study demonstrates significant progression free survival benefit for an mosunetuzumab combination regimen ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results